Medindia

X

Life Science Alley: R&D Makes German Medical Technologies Top in Europe

Tuesday, December 9, 2008 General News J E 4
Advertisement
BERLIN, December 8 Germany is Europe's largest market formedical devices. Total industry revenue in 2007 amounted to EUR 17.3 billion- a nearly 7 percent increase on 2006 figures. Investors looking to enter theGerman and European markets can learn about Germany at Life Science Alley,the largest convention of life science industry professionals in the AmericanMidwest. The conference takes place December 10, 2008 in Minneapolis,Minnesota.

Germany's research landscape is making its medical technologies some ofthe most renowned and trusted worldwide. The country's advanced R&D networkensures that both patients and practitioners have access to the latestmedical technologies.

Currently German medical technology companies spend about 9 percent ofsales revenue on R&D. As a result, products under three years old account for32 percent of industry revenue in Germany. Furthermore, Germany is number twoin the world in patent applications in medical technologies.

Demographic developments suggest that Germany will remain strong inmedical technologies in coming years. By 2015 it is expected that nearly onefifth of Germany's population will be over age 65, increasing the need foradvanced medical technologies and health care.

Existing clusters of manufacturers, research institutes, and clinicsallow companies of all sizes the chance to use Germany's investmentconditions to maximize earnings quickly and efficiently. The availability ofinvestment incentives as well as R&D and labor incentives also makes thecountry an attractive investment location.

Invest in Germany is the inward investment promotion agency of theFederal Republic of Germany. It provides investors with comprehensive supportfrom site selection to the implementation of investment decisions. It can befound at booth 301 at Life Science Alley.Media Contact: Eva Henkel Phone: +49-30-200099-173 Fax: +49-30-200099-111 Email: henkel@invest-in-germany.com

SOURCE Invest in Germany GmbH
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Positive Phase 1 Clinical Trial Results for Transd...
S
New Phase II Data Show Safety of Once-Daily Oral F...